SCHEMBL4277897

SCHEMBL4277897

NC(=O)c1cc(-c2ccc(Nc3cccnc3)cc2)no1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 2/20 0.45
▸ CYP2C9 P11712 9/20 0.44
▸ CYP2C19 P33261 9/20 0.44
▸ CYP3A4 P08684 8/20 0.44
▸ CYP1A2 P05177 7/20 0.44
▸ CYP2D6 P10635 7/20 0.44
▸ MAPT P10636 3/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ JAK2 O60674 1/20 0.44
▸ JAK3 P52333 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ MAPKAPK2 P49137 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ NAMPT P43490 1/20 0.41
▸ CYP2E1 P05181 1/20 0.41
▸ CYP2A6 P11509 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3989788 0.87 MEN1 (0.53) CYP2C19CYP1A2MAPTKDM4ESMN1; SMN2
SCHEMBL3989981 0.86 MEN1 (0.43) CYP2C9CYP2C19CYP3A4CYP1A2CYP2D6
SCHEMBL3986274 0.83 MKNK1 (0.57) CYP2C9CYP2C19CYP3A4CYP1A2CYP2D6
SCHEMBL30516607 0.83 CYP2E1 (0.57) CYP2C9CYP2C19SMN1; SMN2KMT2ANAMPT
SCHEMBL6872027 0.83 CYP2E1 (0.57) CYP2C9CYP2C19SMN1; SMN2KMT2ANAMPT
SCHEMBL3984131 0.78 MEN1 (0.44) TP53CYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL4277903 0.78 CYP2C19 (0.67) CYP2C9CYP2C19CYP3A4CYP1A2CYP2D6
SCHEMBL3981746 0.78 SMN1; SMN2 (0.61) CYP2C19CYP3A4CYP1A2MAPTKDM4E
SCHEMBL3983330 0.77 KMO (0.51) CYP2C9CYP2C19MEN1KMT2ANAMPT
SCHEMBL3990124 0.76 CHUK (0.47) CYP2C19CYP1A2MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893572-B1 FACTOR XA INHIBITORS MILLENNIUM PHARM INC (US) 2016-12-14 — — EP claimed
US-20090298806-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2009-12-03 — — US claimed
EP-1893572-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-05 — — EP claimed
US-20060100193-A1 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-05-11 — — US claimed
WO-2006002099-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-01-05 — — WO claimed
EP-1893572-B1 FACTOR XA INHIBITORS MILLENNIUM PHARM INC (US) 2016-12-14 — — EP disclosed
US-8377974-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-02-19 — — US disclosed
US-20120178733-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2012-07-12 — — US disclosed
US-20090298806-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2009-12-03 — — US disclosed
US-7521470-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-21 — — US disclosed
EP-1893572-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-05 — — EP disclosed
US-20060100193-A1 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-05-11 — — US disclosed
WO-2006002099-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100193-A1 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor TFPI, TFPI2, F12 TP53 2822/4885CYP2C9 13/4885CYP2C19 24/4885
US-20090298806-A1 FACTOR XA INHIBITORS TFPI, F12, F11 TP53 3707/4885CYP2C9 51/4885CYP2C19 75/4885
US-20120178733-A1 FACTOR XA INHIBITORS TFPI, F12, F11 TP53 3707/4885CYP2C9 51/4885CYP2C19 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback